

**In the Specification**

Please replace the last paragraph on page 8 of the Specification with the following amended paragraph:

The bioavailability of the pharmaceutical composition of the present invention (400 mg metaxalone tablets) and that of conventional pharmaceutical composition of metaxalone available commercially (Skelaxin® (corresponding to New Drug Application No. 13-217, 400 mg tablets) were studied. A single-dose, open label, randomized, comparative and two-way crossover pharmacokinetic study with a seven day washout period, was undertaken for the same.